Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Circulating inflammatory mediators and activated immune cells represent a complex systemic physiological state rather than a single molecular target. This category encompasses a diverse array of signaling molecules, such as cytokines (e.g., TNF-alpha, IL-6), chemokines, and lipid mediators, alongside various activated leukocyte populations including T-lymphocytes, monocytes, and neutrophils (Medzhitov, 2008). In pathological states like sepsis, autoimmune disorders, and chronic cardiovascular disease, these components interact in a complex network to drive systemic inflammation and tissue damage (Dinarello, 2000). While therapeutic interventions often aim to modulate this milieu, they typically do so by targeting specific individual components, such as using monoclonal antibodies against specific cytokines, or through broad-spectrum immunosuppression (Hotchkiss et al., 2013). Consequently, this term serves as a descriptive label for the inflammatory environment rather than a discrete, druggable receptor or enzyme. Monitoring these mediators and cell states is crucial for diagnosing inflammatory severity and assessing the efficacy of immunomodulatory treatments in clinical practice (Tanaka et al., 2014). Drugs like Infliximab and Tocilizumab specifically target nodes within this network to alleviate chronic inflammation (Feldmann & Maini, 2001). Overall, understanding the interplay between these mediators and cells is vital for developing precision medicine approaches in immunology.
The mechanism of action involves the neutralization of specific pro-inflammatory cytokines, blockade of their respective receptors, or the broad suppression of immune cell gene expression and proliferation to reduce the systemic inflammatory burden (Feldmann & Maini, 2001; Tanaka et al., 2014).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Circulating inflammatory mediators and activated immune cells.